Meeting
2019 Gastrointestinal Cancers Symposium
Hepatic arterial infusion chemotherapy after sorafenib treatment in patients with advanced hepatocellular carcinoma who are unfit for regorafenib.
Authors
Takeshi Terashima
Advanced Preventive Medical Sciences Research Center, Kanazawa University, Kanazawa, Japan
Takeshi Terashima , Tatsuya Yamashita , Noboru Takata , Kuniaki Arai , Eishiro Mizukoshi , Shuichi Kaneko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 355)
DOI
10.1200/JCO.2019.37.4_suppl.355
Abstract #
355
Poster Bd #
J13
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study.
First Author: Erica S. Tsang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma.
First Author: Jamie Grossman
Poster
2023 ASCO Annual Meeting
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.
First Author: M. Naomi Horiba
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A sequential therapy with sorafenib followed by regorafenib against single-line atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC): Indirect treatment comparisons (ITC) using the RESORCE study.
First Author: Jamie Partridge